Evercore ISI analyst Joshua Schimmer upgraded Alnylam to Outperform from In Line and raised his price target to $110 from $87. In a research note to investors, Schimmer says he has been considering an upgrade for a few weeks, and notes that it is not due to this morning's announcement of positive givosiran Phase 3 Envision topline results, nor is it timed to the ongoing Onpattro launch as near-term consensus numbers may be a "little" aggressive. Instead, he says his constructive view is more about the modularity of Alnylam's RNai 'bioengineering" platform and that the company is in a small group of companies positioned for sustainable growth.

ProQR Therapeutics (PRQR) announced the Annual General Meeting, AGM, of Shareholders will take place on Wednesday, May 22, 2024 at the offices of Allen & Overy LLP, in Amsterdam, the Netherlands. As part of the AGM, Martin Maier, PhD, is nominated for appointment as a non-executive Board Member for a period of four years. Dr. Maier is Senior Vice President Research heading the Oncology group at Alnylam Pharmaceuticals (ALNY).